GERNMEDIUM SIGNALOPERATIONAL10-K

GERN shows early commercialization progress with RYTELO launch evidenced by 553% revenue growth and substantial inventory buildup, though losses remain significant despite improvement.

The company has successfully transitioned from pure R&D to commercial operations with RYTELO generating meaningful initial revenue, but the dramatic inventory increase to $116.6M suggests either aggressive production scaling or potential demand challenges. The improved but still substantial operating losses indicate the company is in early stages of commercialization with uncertain market adoption.

Comparing 2026-03-02 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

Revenue surged 553% to $1.1M reflecting initial RYTELO commercialization, while inventory tripled to $116.6M indicating significant production ramp-up. Operating losses improved 60% to $68.6M and cash burn decreased significantly, though interest expense more than doubled to $18.5M, suggesting increased debt financing. The overall picture shows a biotech successfully launching its first commercial product but facing typical early-stage commercialization challenges with heavy inventory investment and continued substantial losses despite operational improvements.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+553.4%
$163K→$1.1M

Strong top-line growth of 553.4% — accelerating demand or successful expansion into new markets.

Inventory
Balance Sheet
+201.3%
$38.7M→$116.6M

Inventory surged 201.3% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Interest Expense
P&L
+122.6%
$8.3M→$18.5M

Interest expense surged 122.6% — significant debt increase or rising rates materially impacting earnings.

Operating Income
P&L
+60.5%
-$173.7M→-$68.6M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+52.2%
-$174.6M→-$83.5M

Net income grew 52.2% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
+49.2%
-$218.6M→-$111.0M

Operating cash flow surged 49.2% — exceptional cash generation, highest quality earnings signal.

Current Liabilities
Balance Sheet
+26.3%
$88.3M→$111.5M

Current liabilities rose 26.3% — increased short-term obligations, watch current ratio.

Stockholders Equity
Balance Sheet
-19.4%
$280.3M→$225.9M

Equity decreased 19.4% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-03-02
PRIOR — 2025-02-27
ADDED
As of February 20, 2026 , there were 640,544,661 s hares of common stock outstanding.
The risks and uncertainties referred to above include, without limitation, risks and uncertainties related to: (a) whether we are successful in commercializing RYTELO (imetelstat) for the treatment of certain patients with lower-risk myelodysplastic syndromes, or lower-risk MDS, with transfusion dependent anemia; (b) whether the U.S.
Although we have established commercial operations and sales, marketing and distribution infrastructure for RYTELO, we have limited experience in sustaining and scaling these operations and our commercialization efforts may be unsuccessful or less successful than anticipated.
We face competition from existing products, product candidates and technologies, and competitors may develop new products and technologies.
If these products, product candidates or technologies are deemed by the healthcare community to be superior to or more cost-effective than RYTELO, it would significantly impact the development and commercial viability of RYTELO, which would severely and adversely affect our financial results, business and business prospects, and the future of RYTELO, and might cause us to cease operations.
+7 more — sign up free →
REMOVED
As of February 21, 2025 , there were 636,904,470 sh ares of common stock outstanding.
1 Forward Looking Statements This Report, including Business in Part I, Item 1 of this Report and Management s Discussion and Analysis of Financial Condition and Results of Operations in Part II, Item 7 of this Report, contains forward looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause the results of Geron Corporation, or Geron or the Company, to differ materially from those expressed or implied by such forward looking statements.
We have limited experience as a commercial company and our sales, marketing, and distribution of RYTELO may be unsuccessful or less successful than anticipated.
If we do not obtain acceptable prices or adequate reimbursement for RYTELO, the use of RYTELO could be severely limited.
To be commercially successful, RYTELO must be accepted by the healthcare community, which can be slow to adopt or unreceptive to new technologies and products.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →